50 results
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
26 Oct 22
Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
7:48am
the company’s and Celgene’s business and operations, including with respect to human capital management, portfolio rationalization, finance and accounting
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
27 Jul 22
Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
7:44am
the company’s and Celgene’s business and operations, including with respect to human capital management, portfolio rationalization, finance
8-K
EX-99.1
h1q2l
29 Apr 22
Bristol Myers Squibb Reports First Quarter Financial Results for 2022
7:42am
DEFA14A
xan4jxts2xtvwpl6y
20 Apr 22
Additional proxy soliciting materials
4:30pm
8-K
EX-99.1
1sni1alod i72na72e0
3 Mar 22
Upsizing and Early Settlement of Tender Offers
4:16pm
8-K
EX-99.2
ammzrfwfw06a2 7iwq7q
3 Mar 22
Upsizing and Early Settlement of Tender Offers
4:16pm
424B5
2m9 7tu4n
17 Feb 22
Prospectus supplement for primary offering
4:47pm
8-K
EX-99.1
fvnoci uhftmhpl
15 Feb 22
Bristol Myers Squibb Announces Tender Offers
9:16am
424B3
tx4ak w3k
15 Feb 22
Prospectus supplement
9:13am
8-K
EX-99.1
45d88uyq
4 Feb 22
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
7:50am
8-K
EX-99.1
om289ciw89
27 Oct 21
Bristol Myers Squibb Reports Third Quarter Financial Results for 2021
9:46am
8-K
EX-99.1
4q60sq6sufu49 b80
28 Jul 21
Bristol Myers Squibb Reports Second Quarter Financial Results for 2021
7:33am
8-K
EX-99.1
5gmytu 8ezke
29 Apr 21
Bristol Myers Squibb Reports First Quarter Financial Results for 2021
8:38am
DEFA14A
btr2n a84
19 Apr 21
Additional proxy soliciting materials
7:41am